agreements中国InventionsinventorsIP transfer
2018年10月25日

Foreign companies transferring IP out of China: things to know

Inventions made in China

Most foreign companies with R&D sites in China are aware of the fact that inventors having inventions made in China have to obtain permission before they can file patent applications outside of China for these Chinese inventions. It doesn’t matter if the owner of the business is a foreign entity. Patent applications covering inventions “made in China” (on Chinese soil) must first be filed in China or the inventor must obtain permission from the Chinese government to file abroad first.

Inventors from China

All inventors for inventions made in China (including partially made in China) are entitled to be fairly compensated for their work (Article 76 of the Implementation Rules of the Chinese Patent Law). The minimum payment by law is 2% of the business profits unless if an internal policy or employment contract is in place. Rewards can vary, but the final compensation must be fair, with certain minimum requirements (e.g., 3000 RMB for an invention patent).

Additionally, current law stipulates that inventions made by employees (1) during the course of employment or (2) mainly using the employer’s materials and technical means ("Service Inventions") automatically belong to the employer. However, the reach of this ownership goes one year beyond an employee’s resignation, retirement, or change in work. This means that an employer can “claw back” an invention from an employee’s future employer if the employee is working in an area that relates to his responsibilities at the previous employer.

Proposed changes to the law will change this [see update below]. Under the proposed changes, inventions made

(1) mainly using the employer’s materials and technical means; but
(2) not during the course of employment

will no longer automatically belong to the employers (i.e. these inventions are not categorized as service inventions). Instead, inventors will own these inventions provided there are no contracts stipulating otherwise. The proposed changes also dramatically increase the default inventor remuneration amounts, e.g., to at least 20% of the net income generated through an assignment or licensing deal.

[UPDATE] The latest proposed changes have removed the expanded ownership scope described above and have reverted the language back to the original. However, the new proposed changes allow employers to provide incentive schemes to inventors, such as equity, options, or shares. They also allow the employer to give up its rights to file for IP on Service Inventions, perhaps allowing an inventor to file instead?

Heightened Scrutiny for Foreign Parties Transferring IP out of China

Effective as of March 29, 2018, the State Council in China will need to review and approve all transfers of technical intellectual property assets (e.g., patents, registered integrated circuit layout designs, computer software copyrights, plant varieties) from Chinese companies to foreign companies. Transfers include exclusive licenses and transfer of ownership or controlling party. This only applies to Chinese entities, not people. Therefore, it does not include Chinese employees transferring IP rights to their foreign employers.

Summary Thoughts

In view of the changes in the laws, we think it is essential to put into place strong employment agreements and company policies governing invention ownership and remuneration, especially if the company has R&D in China or is working with collaborators in China. Companies should especially take care when setting up agreements that relate to research done in China (e.g., with a Chinese contract research organization) and consider whether employees at these companies previously worked at another “similar-enough” company where their inventions may be “clawed back” by the previous company.

Companies need to be vigilant when it comes to creating IP in China and transferring IP out of China. Not having the right contracts in place or not setting up the proper structures could result in critical issues with a company’s IP assets and could result in future complicated litigations.

About the Author

其他文章

China Top 10 Cases of 2020 – CNIPA Upholds Second Medical Use Patent from University of Bordeaux

2021年5月24日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

Is it Sufficient to Claim an Antibody only by Describing its Antigen?

2018年11月12日
Things may be brewing with respect to antibody inventions. Just how much description is sufficient? After losing in the Federal Circuit, Amgen has decided to ask the US Supreme Court to weigh in on a standard that could vastly influence the pharmaceutical and biotech industry. The story relates to Repatha™, an LDL-lowering drug from Amgen […]

A More Detailed Overview of China’s Patent Term Extension (PTE) System

2024年6月17日
Although PTE has been in the Chinese Patent Law since the 4th Amendment of the law came into effect June 1, 2021, we didn’t really know the exact details of how it operated until the Implementation Regulations and Examination Guidelines (“Implementation Regulations”) were finally released in December 2023. New Rules 77-84 in the Implementation Regulations […]

Compositions Limited by Use: A Cautionary Tale

2022年10月26日
Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]

我们的过去活动

Top crossarrow-right